• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：作者对《FAP激活的前药Z-GP-DAVLBH通过抑制AXL通路抑制骨肉瘤细胞的生长和肺转移》[《中国药理学通报》12 (2022) 1288 - 1304]一文的更正。

Erratum: Author correction to "The FAP-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway" [Acta Pharm Sin B 12 (2022) 1288-1304].

作者信息

Ye Geni, Huang Maohua, Li Yong, Ouyang Jie, Chen Minfeng, Weng Qing, Li Xiaobo, Zeng Huhu, Long Pei, Fan Zepei, Yin Junqiang, Ye Wencai, Zhang Dongmei

机构信息

College of Pharmacy, Jinan University, Guangzhou 510632, China.

Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, Jinan University, Guangzhou 510632, China.

出版信息

Acta Pharm Sin B. 2023 Mar;13(3):1337-1339. doi: 10.1016/j.apsb.2022.12.020. Epub 2023 Feb 1.

DOI:10.1016/j.apsb.2022.12.020
PMID:36970198
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10031275/
Abstract

[This corrects the article DOI: 10.1016/j.apsb.2021.08.015.].

摘要

[本文更正了文章的数字对象标识符：10.1016/j.apsb.2021.08.015。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc97/10031275/65c62dbbdb25/fx2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc97/10031275/b2a442f48a72/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc97/10031275/65c62dbbdb25/fx2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc97/10031275/b2a442f48a72/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc97/10031275/65c62dbbdb25/fx2.jpg

相似文献

1
Erratum: Author correction to "The FAP-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway" [Acta Pharm Sin B 12 (2022) 1288-1304].勘误：作者对《FAP激活的前药Z-GP-DAVLBH通过抑制AXL通路抑制骨肉瘤细胞的生长和肺转移》[《中国药理学通报》12 (2022) 1288 - 1304]一文的更正。
Acta Pharm Sin B. 2023 Mar;13(3):1337-1339. doi: 10.1016/j.apsb.2022.12.020. Epub 2023 Feb 1.
2
The FAP -activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway.FAP激活的前药Z-GP-DAVLBH通过抑制AXL通路抑制骨肉瘤细胞的生长和肺转移。
Acta Pharm Sin B. 2022 Mar;12(3):1288-1304. doi: 10.1016/j.apsb.2021.08.015. Epub 2021 Aug 14.
3
Erratum: Author correction to "TMEM16A inhibits angiotensin II-induced basilar artery smooth muscle cell migration in a WNK1-dependent manner" [Acta Pharm Sin B 11(12) (2021) 3994-4007].勘误：“TMEM16A以WNK1依赖的方式抑制血管紧张素II诱导的基底动脉平滑肌细胞迁移”[《中国药理学报B》11(12)(2021)3994 - 4007]的作者更正。
Acta Pharm Sin B. 2023 Mar;13(3):1340-1343. doi: 10.1016/j.apsb.2023.01.001. Epub 2023 Feb 2.
4
Erratum: Author correction to "Tumor-microenvironment activated duplex genome-editing nanoprodrug for sensitized near-infrared titania phototherapy" [Acta Pharm Sin B (2022) 4224-4234].勘误：《肿瘤微环境激活的双链基因组编辑纳米前药用于敏化近红外二氧化钛光疗》[《药学学报B》（2022年）4224 - 4234]的作者更正。
Acta Pharm Sin B. 2024 Feb;14(2):897-899. doi: 10.1016/j.apsb.2023.09.002. Epub 2023 Sep 7.
5
Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433].勘误：《靶向VEGFR2的抗体与IFNamut融合调节结直肠癌肿瘤微环境并表现出强大的抗肿瘤和抗转移活性》[《药学学报B》11 (2021) 420 - 433]的作者更正。
Acta Pharm Sin B. 2024 Jun;14(6):2790. doi: 10.1016/j.apsb.2024.02.014. Epub 2024 Feb 22.
6
Erratum: Author correction to 'FGF4 protects the liver from immune-mediated injury by activating CaMKK-PINK1 signal pathway to inhibit hepatocellular apoptosis' [Acta Pharm Sin B 14 (2024) 1605-1623].勘误：对“FGF4通过激活CaMKK-PINK1信号通路抑制肝细胞凋亡从而保护肝脏免受免疫介导损伤”一文的作者更正[《药学学报B》14 (2024) 1605-1623]。
Acta Pharm Sin B. 2024 Jun;14(6):2791-2793. doi: 10.1016/j.apsb.2024.04.008. Epub 2024 Apr 9.
7
Erratum: Author correction to 'Pharmacologically targeting molecular motor promotes mitochondrial fission for anti-cancer' [Acta Pharm Sin B 11 (2021) 1853-1866].勘误：“Pharmacologically targeting molecular motor promotes mitochondrial fission for anti-cancer” [《中国药理学报B》11 (2021) 1853-1866]的作者更正。
Acta Pharm Sin B. 2024 May;14(5):2358. doi: 10.1016/j.apsb.2024.02.013. Epub 2024 Feb 21.
8
Erratum: Author correction to 'Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics' [Acta Pharm Sin B 12 (2022) 4458-4471].勘误：“使用六组氨酸金属纳米载体共递送尼日利亚菌素和地西他滨用于焦亡诱导的免疫治疗”[《中国药理学报B》12 (2022) 4458 - 4471]的作者更正。
Acta Pharm Sin B. 2024 May;14(5):2359-2360. doi: 10.1016/j.apsb.2024.02.021. Epub 2024 Feb 29.
9
Erratum: Author correction to "Gas-propelled nanomotors alleviate colitis through the regulation of intestinal immunoenvironment-hematopexis-microbiota circuits" [Acta Pharm Sin B 14 (2024) 2732-2747].勘误：《气体驱动纳米马达通过调节肠道免疫环境-血液结合素-微生物群回路缓解结肠炎》[《药学学报B》14 (2024) 2732-2747]的作者更正。
Acta Pharm Sin B. 2024 Sep;14(9):4193. doi: 10.1016/j.apsb.2024.06.005. Epub 2024 Jun 15.
10
Erratum: Author correction to 'Discovery of the radio-protecting effect of ecliptae herba, its constituents and targeting p53-mediated apoptosis and ' [Acta Pharm Sin B 13 (2023) 1216-1230].勘误：《墨旱莲及其成分的辐射防护作用与靶向p53介导的细胞凋亡》的作者更正 [《中国药理学通报》13 (2023) 1216 - 1230] 。
Acta Pharm Sin B. 2023 Jun;13(6):2815-2816. doi: 10.1016/j.apsb.2023.03.026. Epub 2023 Mar 31.